- Home
- GLBZ vs BIVI Comparison
GLBZ vs BIVI Comparison
Compare GLBZ & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLBZ | BIVI |
|---|---|---|
| Founded | 1949 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 14.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLBZ | BIVI |
|---|---|---|
| Price | $3.96 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 61.7K |
| Earning Date | 10-31-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $12,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $460.41 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $3.76 | $1.25 |
| 52 Week High | $6.25 | $27.00 |
Technical Indicators
Market Signals| Indicator | GLBZ | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 42.45 |
| Support Level | $4.22 | $1.45 |
| Resistance Level | $4.44 | $1.63 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 45.95 | 35.90 |
Price Performance
Historical ComparisonAbout GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.